Trial Profile
Atezolizumab in Combination With Bevacizumab and Chemotherapy Versus Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer - a Randomized Phase III Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Doxorubicin; Paclitaxel
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 25 Jul 2022 Planned primary completion date changed from 1 Dec 2023 to 1 Jan 2024.
- 25 Jul 2022 Status changed from recruiting to active, no longer recruiting.
- 07 Jun 2022 Trial design (As of 9 Feb 2022; n=461) presented at the 58th Annual Meeting of the American Society of Clinical Oncology.